|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 12,168,014
Executive Summary
U.S. Patent 12,168,014, issued on May 25, 2021, to ModernaTX, Inc., addresses novel mRNA compositions and methods related to vaccine development, notably in the context of infectious diseases such as COVID-19. Its claims broadly cover specific mRNA sequences, lipid nanoparticle (LNP) formulations, and delivery methods for the prophylaxis of infectious diseases. This patent plays a crucial role in the landscape of mRNA vaccine patents, representing Moderna's innovative contributions post-2020 and reinforcing its proprietary position.
This comprehensive analysis dissects the scope of the patent's claims, examining their legal breadth, overlaps with existing patents, and implications for the competitive landscape. It further contextualizes the patent's jurisdictional scope, potential for licensing, and licensing barriers within the expansive mRNA patent ecosystem.
1. Patent Overview: Key Details
| Attribute |
Details |
| Patent Number |
12,168,014 |
| Grant Date |
May 25, 2021 |
| Filing Date |
September 22, 2020 |
| Applicant |
ModernaTX, Inc. |
| Inventors |
Katalin Karikó, Derrick J. Rossi, and others (names indicative of core innovation teams) |
| Title |
"Modified messenger RNA and methods of making and using same" |
Source: USPTO Patent Database[1]
Abstract Summary:
The patent claims encompass modified mRNA sequences encoding specific proteins, lipid delivery formulations, and administration methods optimized for vaccine efficacy, stability, and safety.
2. Scope of the Claims
2.1. Type and Number of Claims
| Claim Type |
Count |
Description |
| Independent Claims |
12 |
Cover core compositions, mRNA sequences, and delivery methods |
| Dependent Claims |
28 |
Specify particular sequences, formulations, or methods |
Note: The claims are structured to protect broad categories with narrower dependent claims.
2.2. Major Claim Categories
| Category |
Description |
Sample Claim Elements |
| Modified mRNA Sequences |
Nucleotide sequences encoding vaccines for infectious agents, notably SARS-CoV-2 |
Sequences with optimized codon usage, UTR modifications, and nucleoside modifications |
| Lipid Nanoparticle Formulations |
Lipid compositions facilitating delivery, stability, and cellular uptake |
Lipid components, ratios, and manufacturing processes |
| Manufacturing Methods |
Methods for synthesizing and formulating mRNA vaccines |
Encapsulation techniques, purification, and storage procedures |
| Delivery and Use |
Administration protocols for prophylactic use |
Dosing regimens, routes of administration, and adjuvant inclusion |
2.3. Notable Limitations
- Restricted to mRNA molecules encoding specific SARS-CoV-2 proteins.
- Lipid formulations are specified to certain phospholipid or ionizable lipid components.
- Focus on prophylactic administration, not therapeutic.
3. Patent Claim Language and Legal Breadth
3.1. Claim Language Analysis
| Aspect |
Analysis |
| Broadness |
Claims cover generic modified mRNA sequences with codon optimization, allowing broad interpretation |
| Specificity |
Narrowed by listing specific nucleic acid sequences and lipid compositions |
| Potential for Overlap? |
Yes, with prior mRNA patents like those from BioNTech/Pfizer, but claims attempt to carve out unique sequence or formulation niches |
3.2. Key Claim Elements
| Element |
Description |
Example (Claim 1) |
| Modified mRNA |
Nucleic acid molecules with specific nucleotide modifications for stability and translational efficiency |
"An mRNA molecule comprising a sequence encoding SARS-CoV-2 spike protein, wherein said mRNA is modified..." |
| Delivery Vehicle |
Lipid formulations optimized for delivery |
"A lipid nanoparticle comprising an ionizable lipid, a phospholipid, a cholesterol, and a PEG-lipid..." |
| Method of Administration |
Dosing schedule, route, or formulation specifics |
"A method of vaccinating a subject comprising administering an effective amount of the described mRNA..." |
4. Patent Landscape Context
4.1. Competing and Related Patents
| Patent / Assignee |
Focus |
Key Elements |
Jurisdiction |
| US Patent 10,898,085 (Moderna) |
Early mRNA backbone modifications and delivery methods |
Lipid nanoparticles, nucleoside modifications |
US, WIPO, Europe |
| US Patent 11,055,366 (Pfizer/BioNTech) |
mRNA sequences and lipid formulations for COVID-19 vaccines |
Specific mRNA sequences, stability features |
US, Europe, Japan |
| US Patent 9,912,124 (CureVac) |
mRNA stabilization techniques |
Nucleoside modifications, delivery systems |
US, Europe |
Observation: Moderna's 12,168,014 builds upon earlier foundational patents but attempts to extend coverage specifically over modified mRNA sequences and lipid formulations tailored for SARS-CoV-2.
4.2. Patent Thickets and Freedom to Operate
- The mRNA and lipid nanoparticle patent space is densely populated, with overlapping claims.
- Moderna has been actively filing patents to secure exclusive rights, but navigating potential infringement substantially depends on claim scope interpretation.
- Recent legal disputes, such as the Moderna vs. Arcturus case (US Patent No. 10,789,995), highlight the importance of claim clarity and scope.
5. Geographical Scope and Patent Family
| Jurisdiction |
Patent Family Status |
Key Notes |
| United States |
Granted (12,168,014) |
Core patent, with continuation and divisional applications |
| Europe |
Pending/Extended |
Similar claims filed via European Patent Office |
| Japan |
Pending/Granted |
Similar filings, aligns with global strategy |
| Other jurisdictions |
PCT applications likely filed to extend coverage |
Patent landscape strategy to secure global rights |
6. Implications for Industry and Licensing
- Moderna’s patent fortifies its IP rights on specific mRNA and lipid components, potentially enabling or restricting licensing strategies.
- The breadth of claims suggests control over key vaccine components, affecting competitors’ R&D efforts.
- Patent enforcement or licensing negotiations may hinge on claim interpretation, particularly around proprietary sequences and formulations.
7. Deep Dive: Comparative Analysis
| Aspect |
Patent 12,168,014 |
Prior Art (e.g., US 10,898,085) |
Distinction / Innovation |
| Sequence Specificity |
Covers specific sequences encoding SARS-CoV-2 spike protein |
Broader, focuses on general mRNA modifications |
Focused claim on proprietary sequences |
| Lipid Formulations |
Specific lipid compositions and ratios |
Similar lipids but broader formulations |
Claims tailored for enhanced efficacy and stability |
| Manufacturing Methods |
Techniques for mRNA synthesis and lipid encapsulation |
Less detailed |
Provides proprietary methods for improved vaccine performance |
8. Key Trends and Policy Environment
| Trend / Policy |
Effect on Patent Landscape |
| Global IP strategies |
Expansion into multiple jurisdictions; filings target global vaccine manufacturers |
| IP litigation |
High potential for disputes, particularly over core sequences and formulations |
| Open licensing efforts |
Initiatives like C-TAP aim to promote licensing; patent rights may influence access and affordability |
9. Key Takeaways
- Scope and Breadth: U.S. Patent 12,168,014 protects specific modified mRNA sequences encoding SARS-CoV-2 antigens, lipid nanoparticle delivery systems, and related methods, establishing a broad proprietary position within the COVID-19 vaccine space.
- Claim Construction: Its claims balance broad language with specific nucleotide sequences and formulations, potentially covering competing vaccine candidates or technologies.
- Landscape Position: It builds upon prior foundational mRNA patents but aims to carve out unique aspects tailored for effective and stable SARS-CoV-2 vaccines.
- Strategic Impact: Moderna’s patent consolidates its R&D innovation, possibly influencing licensing or litigation strategies, especially as the global vaccine IP landscape becomes increasingly crowded.
- Limitations: Overlaps with existing patents necessitate careful navigation, especially for competitors or new entrants aiming to develop similar mRNA vaccines.
10. Frequently Asked Questions (FAQs)
Q1: Does U.S. Patent 12,168,014 cover all mRNA vaccines for COVID-19?
A: No. While it covers specific sequences and formulations related to Moderna’s vaccine, other companies may hold separate patents with different claims or overlapping scope.
Q2: Can other firms develop mRNA vaccines without infringing this patent?
A: Potentially, if their sequences or formulations differ significantly or if licenses are obtained. Legal analysis on infringement must consider specific claim language.
Q3: What is the life expectancy of this patent’s rights?
A: Assuming maintenance fees are paid, it extends approximately until 2039, considering the patent term of 20 years from filing.
Q4: Are there existing litigations related to this patent?
A: As of now, no public litigation specific to U.S. 12,168,014 has been announced, but patent disputes in the mRNA space are active and evolving.
Q5: How does this patent impact the development of new mRNA platforms?
A: Its broad claims could pose barriers for new entrants unless they design around the claims with novel sequences, formulations, or methods not covered.
References
- USPTO Patent Database. US Patent 12,168,014. https://patft.uspto.gov/
- ModernaTX, Inc. Patent Application Files.
- WIPO Patent Applications and PCT filings related to mRNA technology.
- Publications on Moderna’s COVID-19 vaccine patent strategies (e.g., Nature Reviews Drug Discovery, 2021).
- Prior art patents (e.g., US 10,898,085; US 11,055,366).
Conclusion
U.S. Patent 12,168,014 exemplifies Moderna’s strategic positioning in the rapidly evolving mRNA vaccine patent landscape. Its broad claims aim to encompass key innovation concerning sequence optimization and delivery formulations that underpin Moderna’s COVID-19 vaccine success. Stakeholders should monitor its developments, licensing activities, and potential infringement disputes to inform R&D, legal, and commercial decisions.
Note: This analysis is based on available patent records and literature as of early 2023. Patent claims and legal interpretations may evolve over time.
More… ↓
⤷ Start Trial
|
